Sonoma Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sonoma Pharmaceuticals generated cash of -$2,398,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,676,000 last year. Net change in cash is therefore -$692,000.
Cash Flow
| 2015 | -6.69M | 875K | 6.60M |
|---|---|---|---|
| 2016 | -8.74M | 4.19M | 6.03M |
| 2017 | -8.16M | 18.22M | -32K |
| 2018 | -12.43M | -201K | 5.24M |
| 2019 | -11.71M | -131K | 5.49M |
| 2020 | -4.59M | 3.64M | 1.02M |
| 2021 | -3.37M | 388K | 3.30M |
| 2022 | -4.24M | -99K | 7.39M |
| 2023 | -6.15M | -258K | 2.48M |
| 2024 | -2.39M | -2K | 1.67M |
SNOA Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.82M | 7.39M | 4.22M | 3.69M | 3.68M | 10.06M | 17.46M | 7.46M | 6.13M | 5.48M |
Operating activities | ||||||||||
Net income | -4.83M | -5.15M | -5.08M | -3.95M | -2.94M | -11.79M | -14.32M | 9.27M | -10.16M | -8.20M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 176K | 125K | 186K | 227K | 312K | 453K | 490K | 248K | 244K | 253K |
Stock-based compensation expense | 516K | 669K | 382K | 371K | 839K | 1.63M | 2.41M | 2.14M | 2.34M | 1.77M |
| Deferred income tax benefit | 516K | 669K | 382K | 371K | 839K | 1.63M | 2.41M | 2.14M | 2.34M | 1.77M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -230K | 62K | 1.97M | 2.60M | -2.19M | -1.16M | 11K | 34K | -1.28M | 40K |
Inventories | 184K | 44K | -100K | -65K | 323K | -779K | -583K | -675K | -382K | -627K |
Accounts payable | -278K | -864K | -157K | -796K | 336K | 5K | 9K | -58K | 429K | 222K |
Cash generated by operating activities | -2.39M | -6.15M | -4.24M | -3.37M | -4.59M | -11.71M | -12.43M | -8.16M | -8.74M | -6.69M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -17K | -269K | -137K | -179K | -206K | -100K | -187K | -394K | -345K | -139K |
Acquisitions Net | 0 | 0 | 0 | 0 | 2.7M | 0 | 0 | 18.63M | 0 | 0 |
Cash generated by investing activities | -2K | -258K | -99K | 388K | 3.64M | -131K | -201K | 18.22M | 4.19M | 875K |
Financing activities | ||||||||||
Common Stock Issued | 1.78M | 2.86M | 7.55M | 2.28M | 1.37M | 5.97M | 5.46M | 98K | 0 | 6.78M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -481K | -120K | -467K | -481K | -347K | -478K | -280K | -130K | -119K | -176K |
Cash used in financing activities | 1.67M | 2.48M | 7.39M | 3.30M | 1.02M | 5.49M | 5.24M | -32K | 6.03M | 6.60M |
Net Change In Cash | -692K | -3.57M | 3.17M | 529K | 2K | -6.37M | -7.39M | 9.99M | 1.33M | 656K |
Cash at end of period | 3.12M | 3.82M | 7.39M | 4.22M | 3.69M | 3.68M | 10.06M | 17.46M | 7.46M | 6.13M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |